PROMINENT- PEMAFIBRATE TO REDUCE CARDIOVASCULAR OUTCOMES BY REDUCING TRIGLYCERIDES IN PATIENTS WITH DIABETES

StatusActive
Effective start/end date31/03/17 → 31/03/21

Funding

  • Kowa Research Institute, Inc.: $30,286.80
View all
View less

Keywords

  • Biotechnology & Drug Development, Cardiovascular Research